Label (71610 0948 30)
Pregabalin Capsule
Product Images NDC 71610-948
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71610-948). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Aphena (Aphena)
Chemical Structure (Pregabalin 01)
Figure 1 (Pregabalin 02)
Figure 2 (Pregabalin 03)
This text provides information about the percent of patients who improved while taking Pregabalin 100 mg. It shows the time intervals and pain improvement percentages from the baseline.*
Figure 3 (Pregabalin 04)
This data shows the percentage of patients whose pain improved when taking different doses of Pregabalin (300mg, 150mg, 75mg) two times a day compared to a placebo. The chart ranges from 0% to 100% for improvement in pain from the baseline.*
Figure 4 (Pregabalin 05)
This text provides information on the percent of patients improved with different treatments, specifically Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and Placebo. The data shows the percent of improvement in pain from baseline, although specific numeric values are unclear due to errors.*
Figure 5 (Pregabalin 06)
This information shows the percent of patients improved with different treatments: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and Placebo. The graph displays the percent improvement in pain from baseline over a range of values from 20 to 100.*
Figure 6 (Pregabalin 07)
Figure 7 (Pregabalin 08)
Seizure Reduction data for different studies under different dosing frequencies (BID and TID) are presented. The median percentage change from baseline in seizures is provided for each study. The studies mentioned are labeled as E1, E2, and E3. The data appears to involve a drug called Pacabo, with the doses possibly indicated in mg/day.*
Figure 9 (Pregabalin 09)
Figure 10 (Pregabalin 10)
Figure 11 (Pregabalin 11)
Figure 12 (Pregabalin 12)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
